Prelude Therapeutics Inc
PRLD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001678660
No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:55 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $99.5M (819.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 10, 2026 | Mar 10, 2025 | Feb 15, 2024 | Mar 15, 2023 | Mar 16, 2022 |
| Revenue | $12.1M | $7.00M | – | – | – |
| Operating expenses | $116.7M | $146.7M | $132.3M | $123.5M | $113.7M |
| Research and development | $94.3M | $118.0M | $103.4M | $92.9M | $86.8M |
| Selling, general and administrative | $22.4M | $28.7M | $28.9M | $30.7M | $27.0M |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M |
| Income tax | $0 | – | – | – | – |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M |
| EPS, basic | $-1.29 | $-1.68 | $-2.02 | $-2.44 | – |
| EPS, diluted | $-1.29 | $-1.68 | $-2.02 | $-2.44 | – |
| Weighted shares, basic | 77.0M | 75.8M | 60.4M | 47.4M | – |
| Weighted shares, diluted | 77.0M | 75.8M | 60.4M | 47.4M | – |
| Margins and growth | |||||
| Operating margin | -861.3% | -1995.9% | – | – | – |
| Net margin | -819.6% | -1816.8% | – | – | – |
| Revenue growth, year over year | +73.4% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 10, 2026 | Mar 10, 2025 | Feb 15, 2024 | Mar 15, 2023 | Mar 16, 2022 |
| Cash and equivalents | $35.3M | $12.5M | $25.3M | $30.6M | $31.8M |
| Short-term investments | $68.0M | $121.1M | $207.6M | $171.1M | $259.4M |
| Total current assets | $105.7M | $135.9M | $235.6M | $204.4M | $295.1M |
| Property, plant and equipment | $5.11M | $6.77M | $7.33M | $4.91M | $3.93M |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M |
| Accounts payable | $3.98M | $7.73M | $4.58M | $6.78M | $7.84M |
| Total current liabilities | $53.0M | $25.6M | $21.8M | $21.7M | $19.2M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M |
| Shareholders' equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 10, 2026 | Mar 10, 2025 | Feb 15, 2024 | Mar 15, 2023 | Mar 16, 2022 |
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M |
| Capital expenditures | $67.0K | $764.0K | $3.51M | $3.02M | $2.32M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M | -$85.9M |
| Depreciation and amortization | $1.71M | $1.77M | $1.17M | $1.32M | $915.0K |
| Stock-based compensation | $11.9M | $21.3M | $25.6M | $25.1M | $20.9M |
| Investing cash flow | $53.5M | $90.2M | -$34.6M | $81.7M | -$263.8M |
| Financing cash flow | $24.8M | -$120.0K | $136.4M | $815.0K | $164.9M |
| Net change in cash | $22.0M | -$12.8M | -$5.31M | -$1.22M | -$182.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 98.1% | 304.9% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 6, 2026 | 79.8M | +41.0% | SEC |
| May 7, 2026 | 79.6M | +41.1% | SEC |
| Mar 6, 2026 | 63.0M | +14.2% | SEC |
| Nov 10, 2025 | 62.9M | +14.2% | SEC |
| Aug 11, 2025 | 56.6M | +2.9% | SEC |
| Apr 30, 2025 | 56.5M | +2.8% | SEC |
| Mar 6, 2025 | 55.2M | +0.4% | SEC |
| Nov 4, 2024 | 55.0M | +0.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.